Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer
Joe Stephenson, John Nemunaitis(Mary Crowley Cancer Research Center), Anil A. Joy(University of Alberta), Julie Martin, Ying‐Ming Jou(Merck & Co., Inc., Rahway, NJ, USA (United States)), Da Zhang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Paul Statkevich(Merck & Co., Inc., Rahway, NJ, USA (United States)), Siu‐Long Yao(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yali Zhu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Honghong Zhou(Merck & Co., Inc., Rahway, NJ, USA (United States)), Karen Small(Merck & Co., Inc., Rahway, NJ, USA (United States)), Rajat Bannerji(Merck & Co., Inc., Rahway, NJ, USA (United States)), Martin J. Edelman(University of Maryland, Baltimore)
Cited by 100
Abstract
Related Papers
No related papers found
Powered by citation graph analysis